New hope for kids with lupus: belimumab shows promise in chinese trial

NCT ID NCT04908865

Completed Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether adding belimumab to standard treatment is safe and effective for Chinese children aged 5 to 17 with active lupus. 67 participants received belimumab plus their usual therapy. The main goal was to check for serious side effects and see if lupus disease activity decreased over 52 weeks. Results showed that many children had a significant reduction in disease activity, though some experienced infections or allergic reactions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belimumab
What this could lead to: If successful, this could provide a treatment option for children with lupus that helps control disease activity and reduce flares.
What could go wrong: This is a Phase 4 study in a specific population (Chinese children), so results may not apply to other groups. Side effects like infections and allergic reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

GSK Investigational Site

Beijing, 100045, China
GSK Investigational Site

Changchun, 130021, China
GSK Investigational Site

Changsha, 410007, China
GSK Investigational Site

Chongqing, 400014, China
GSK Investigational Site

Hangzhou, 310052, China
GSK Investigational Site

Nanjing, 210011, China
GSK Investigational Site

Shanghai, 361006, China
GSK Investigational Site

Suzhou, 215007, China
GSK Investigational Site

Xi'an, 710054, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.